Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Epcoritamab Monotherapy in Patients with Relapsed or Refractory LBCL Not Previously Exposed to CAR T: Subanalysis of the Epcore NHL-1 Trial

Yasmin H. Karimi, Michael Roost Clausen, David John Lewis, Wojciech Jurczak, Michelle Poon, Tae Min Kim, Young Rok Do, Pieternella Lugtenburg, Kristin Conte, David Soong, Barbara D'Angelo Månsson, Zhu Li, Christian Eskelund, Martin Hutchings

Blood (2024) 144 (Supplement 1): 1737.

https://doi.org/10.1182/blood-2024-199225

Published: 2024

Journal Articles

Plamotamab: First Presentation of Subcutaneous Administration in a Phase 1 Dose Escalation Study in Heavily Pretreated R/R NHL Patients Who Had Prior CAR-T Cell Therapy

Peter A. Riedell, Krish Patel, Vanessa Dunleavy, Yasmin H. Karimi, Nirav N. Shah, Vincent Ribrag, Loic Ysebaert, Robin Noel, Gabriel Brisou, Justin Kline, Chet Bohac, Carlos Naranjo, Jitendra Kanodia, Jacky Woo, Nancy Chen, Jean-Marie Michot, Benoîtt Tessoulin, Sairah Ahmed

Blood (2024) 144 (Supplement 1): 4497.

https://doi.org/10.1182/blood-2024-203668

Published: 2024

Journal Articles

Three-Factor Prediction Model for Grade 2+ Cytokine Release Syndrome in Large B-Cell Lymphoma Patients Receiving Epcoritamab Monotherapy

Catherine Thieblemont, Yasmin H. Karimi, Chan Y Cheah, Michael Roost Clausen, Kim Linton, Tycel J. Phillips, Franck Morschhauser, Martin Hutchings, Rebekah Conlon, Saurabh Mukhopadhyay, Aurelie Le Maitre, Yu Deng, Mariana Sacchi, Thomas Doerr, Minh Dinh, William Palo, Loretta Nastoupil

Blood (2024) 144 (Supplement 1): 4491.

https://doi.org/10.1182/blood-2024-200957

Published: 2024

Journal Articles

Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 4406.

https://doi.org/10.1182/blood-2024-194601

Published: 2024

Journal Articles

Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial

Lori A. Leslie, Chan Y. Cheah, Franck Morschhauser, Justin M. Darrah, Joshua Brody, David Belada, Juraj Duras, Joost S.P. Vermaat, Gerardo Musuraca, Kojo Osei-Bonsu, Yi Hao, Kimberly G. Archer, Monica Wielgos-Bonvallet, Ali Rana, Yasmin H. Karimi

Blood (2024) 144 (Supplement 1): 3106.

https://doi.org/10.1182/blood-2024-199652

Published: 2024

Journal Articles

Risk Factors for Severe Infection in Patients Receiving Bispecific Antibody Therapies for Lymphoma

Iman Ahmed, Victoria Nachar, Lydia Benitez, Shannon A. Carty, Dahlia Sano, Ryan A. Wilcox, XI Yang, Jonathan Weiss, Yasmin H. Karimi

Blood (2024) 144 (Supplement 1): 3105.

https://doi.org/10.1182/blood-2024-205406

Published: 2024

Journal Articles

3-Year Update from the Epcore NHL-1 Trial: Epcoritamab Leads to Deep and Durable Responses in Relapsed or Refractory Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 4480.

https://doi.org/10.1182/blood-2024-198714

Published: 2024

Journal Articles

Risk Factors for Cytokine Release Syndrome in Patients Receiving Bispecific Antibodies for B-Cell Lymphoma: A Single-Center, Retrospective Cohort Study

XI Yang, Iman Ahmed, Victoria Nachar, Shannon A. Carty, Ryan A. Wilcox, Jonathan Weiss, Dahlia Sano, Tycel J. Phillips, Yasmin H. Karimi

Blood (2024) 144 (Supplement 1): 4477.

https://doi.org/10.1182/blood-2024-211076

Published: 2024

Journal Articles

Outcomes of Sequenced Therapy in Mantle Cell Lymphoma in Patients Treated with First-Line Autologous Stem Cell Transplantation and Second-Line BTK Inhibitor

Michael McLane, Victoria Nachar, Shannon A. Carty, Mark S Kaminski, Tycel J. Phillips, Dahlia Sano, Jonathan Weiss, Ryan A. Wilcox, Iman Ahmed, Yasmin H. Karimi

Blood (2024) 144 (Supplement 1): 6348.

https://doi.org/10.1182/blood-2024-209170

Published: 2024

Journal Articles

Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study

Blood (2024) 144 (Supplement 1): 111.

https://doi.org/10.1182/blood-2024-199330

Published: 2024

Journal Articles

Assessment of Tumor Metabolic Volume (TMV) As a Predictor of Outcomes in Patients with Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma (PMBCL)

Henry Dumke, Kellen Fitzpatrick, Tycel Phillips, Mark S Kaminski, Shannon A. Carty, Ryan A. Wilcox, Dahlia Sano, Malathi Kandarpa, Avery Polk, Benjamin L Viglianti, Yasmin H. Karimi

Blood (2024) 144 (Supplement 1): 6462.

https://doi.org/10.1182/blood-2024-203822

Published: 2024

Journal Articles

Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab, Gemcitabine, and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A Match-Adjusted Comparative Analysis

Blood (2024) 144 (Supplement 1): 7760.

https://doi.org/10.1182/blood-2024-203876

Published: 2024

Journal Articles

Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Glofitamab or Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A Match-Adjusted Comparative Analysis

Blood (2024) 144 (Supplement 1): 7757.

https://doi.org/10.1182/blood-2024-203540

Published: 2024

Journal Articles

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy

Blood (2024) 143 (16): 1565–1575.

https://doi.org/10.1182/blood.2023022432

Published: 2024

Journal Articles

Cost Effectiveness of Mosunetuzumab and CAR-T Cell Therapy in Relapsed/Refractory Follicular Lymphoma

Manisha Lin, Jonathan Weiss, Tycel J. Phillips, Dahlia Sano, Shannon A. Carty, Monalisa Ghosh, Iman Ahmed, Victoria Nachar, David Hutton, Yasmin H. Karimi

Blood (2023) 142 (Supplement 1): 256.

https://doi.org/10.1182/blood-2023-182244

Published: 2023

Journal Articles

Epcoritamab SC + R-Mini-CHOP Leads to High Complete Metabolic Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: First Disclosure from Arm 8 of the Epcore NHL-2 Trial

Joost S.P Vermaat, Joshua Brody, Juraj Ďuraš, Yasmin H. Karimi, Chan Y. Cheah, Justin M. Darrah, Gerardo Musuraca, Franck Morschhauser, Daniela Hoehn, Ali Rana, Yaou Song, Pegah Jafarinasabian, David Belada

Blood (2023) 142 (Supplement 1): 4457.

https://doi.org/10.1182/blood-2023-180935

Published: 2023

Journal Articles

Epcoritamab SC + GemOx Leads to High Complete Metabolic Response Rates in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ineligible for Autologous Stem Cell Transplant: Updated Results from Epcore NHL-2

Joshua Brody, Judit Mészáros Joergensen, David Belada, Regis T. Costello, Marek Trněný, Umberto Vitolo, David Lewis, Yasmin H. Karimi, Anna Maria Sureda Balari, Marc André, Björn E. Wahlin, Pieternella Lugtenburg, Faith Galderisi, Aqeel Abbas, Yaou Song, Malene Risum, Raul Cordoba

Blood (2023) 142 (Supplement 1): 3092.

https://doi.org/10.1182/blood-2023-180246

Published: 2023

Journal Articles

A Multi-Center Study: Outcomes Among Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients with CD20 Loss

Radhika Takiar, Wern Lynn Ng, Eshana Shah, Philip S. Boonstra, Yasmin H. Karimi, Shannon A. Carty, Ryan A. Wilcox, Carlos A. Murga Zamalloa, Grzegorz S. Nowakowski, Tycel J. Phillips

Blood (2022) 140 (Supplement 1): 9510–9511.

https://doi.org/10.1182/blood-2022-158825

Published: 2022

Journal Articles

Dose-Escalation Study of Azacitidine Followed By High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in High-Risk Acute Myeloid Leukemia (AML)

Yasmin H Karimi, MD, Nitin Jain, MD, Margaret Green, Lucy A Godley, MD, PhD, Howie Lawrence Weiner, Gregory Malnassy, Noreen Fulton, Andrew Artz, MD MS, Hongtao Liu, MDPhD, Michael J. Thirman, MD, Michael Daunov, Richard A. Larson, MD, Wendy Stock, MD, Olatoyosi Odenike, MD

Blood (2015) 126 (23): 3777.

https://doi.org/10.1182/blood.V126.23.3777.3777

Published: 2015

NARROW

Efficacy and Safety of Epcoritamab Monotherapy in Patients with Relapsed or Refractory LBCL Not Previously Exposed to CAR T: Subanalysis of the Epcore NHL-1 Trial

Plamotamab: First Presentation of Subcutaneous Administration in a Phase 1 Dose Escalation Study in Heavily Pretreated R/R NHL Patients Who Had Prior CAR-T Cell Therapy

Three-Factor Prediction Model for Grade 2+ Cytokine Release Syndrome in Large B-Cell Lymphoma Patients Receiving Epcoritamab Monotherapy

Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma

Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial

Risk Factors for Severe Infection in Patients Receiving Bispecific Antibody Therapies for Lymphoma

3-Year Update from the Epcore NHL-1 Trial: Epcoritamab Leads to Deep and Durable Responses in Relapsed or Refractory Large B-Cell Lymphoma

Risk Factors for Cytokine Release Syndrome in Patients Receiving Bispecific Antibodies for B-Cell Lymphoma: A Single-Center, Retrospective Cohort Study

Outcomes of Sequenced Therapy in Mantle Cell Lymphoma in Patients Treated with First-Line Autologous Stem Cell Transplantation and Second-Line BTK Inhibitor

Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study

Assessment of Tumor Metabolic Volume (TMV) As a Predictor of Outcomes in Patients with Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma (PMBCL)

Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab, Gemcitabine, and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A Match-Adjusted Comparative Analysis

Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Glofitamab or Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A Match-Adjusted Comparative Analysis

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy

Cost Effectiveness of Mosunetuzumab and CAR-T Cell Therapy in Relapsed/Refractory Follicular Lymphoma

Epcoritamab SC + R-Mini-CHOP Leads to High Complete Metabolic Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: First Disclosure from Arm 8 of the Epcore NHL-2 Trial

Epcoritamab SC + GemOx Leads to High Complete Metabolic Response Rates in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ineligible for Autologous Stem Cell Transplant: Updated Results from Epcore NHL-2

A Multi-Center Study: Outcomes Among Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients with CD20 Loss

Dose-Escalation Study of Azacitidine Followed By High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in High-Risk Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only